# Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

> **NCT02309580** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- T-cell Lymphoma
- Relapsed and Refractory T-cell Lymphoma

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02309580
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2023-05-08
- **Final completion:** 2023-05-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02309580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02309580, "Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02309580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*